All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eftansomatropin
Therapeutic Area: Endocrinology Product Name: TJ101
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Genexine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2020
Details:
The phase 3 trial is a study designed to assess the safety, efficacy and pharmacokinetics of eftansomatropin in PGHD. The primary objective is to demonstrate non-inferiority of eftansomatropin administered in subcutaneous injection, compared to the active control Norditropin®.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TTP399
Therapeutic Area: Endocrinology Product Name: TTP399
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2020
Details:
The data presented at EASD add to the growing body of evidence supporting the potential of TTP399 to meet the urgent yet still unmet need for an adjunctive therapy for patients living with T1D that improves disease management and health outcomes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Insulin
Therapeutic Area: Endocrinology Product Name: ORMD-0801
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
Details:
The presentation will highlight study titled: Evening oral insulin (ORMD-0801) glycaemic effects in uncontrolled type 2 diabetes patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Enavogliflozin
Therapeutic Area: Endocrinology Product Name: DWP16001
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
Details:
Enavogliflozin administered in conjunction with diet and exercise showed statistically significant decrease in glycated hemoglobin (HbA1c) levels in comparison to the placebo starting from week 4, in type 2 diabetes patients with uncontrolled blood sugar level.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TTP399
Therapeutic Area: Endocrinology Product Name: TTP399
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
Details:
The oral presentation will illustrate findings from the Simplici-T1 Trial which showed that activation of glucokinase by TTP399 enhances glycaemic control in patients with Type 1 Diabetes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TransCon PTH
Therapeutic Area: Endocrinology Product Name: TransCon PTH
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
Details:
The study demonstrated that TransCon PTH eliminated standard of care (i.e. off active vitamin D and ≤ 500 mg per day of calcium supplements) in 82 percent of subjects across all dosage arms.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Paltusotine
Therapeutic Area: Endocrinology Product Name: CRN00808
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2020
Details:
A presentation on the company’s orally administered, small molecule adrenocorticotropic hormone (ACTH) antagonist was selected for a late-breaking session at the virtual European Congress of Endocrinology (eECE).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MS1819,Porcine enzyme replacement therapy
Therapeutic Area: Endocrinology Product Name: MS1819
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
Details:
In the primary efficacy analysis, patients receiving MS1819 in combination with PERT therapy achieved a clinically meaningful improvement in the coefficient of fat absorption (CFA) at each of the three dose levels, with no adverse safety events reported.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eftansomatropin
Therapeutic Area: Endocrinology Product Name: TJ101
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2020
Details:
The Phase 3 trial is a multi-center, randomized, open-label, active-controlled clinical study designed to assess the safety, efficacy and pharmacokinetics of eftansomatropin in PGHD.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MS1819,Porcine enzyme replacement therapy
Therapeutic Area: Endocrinology Product Name: MS1819
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $22.1 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 20, 2020
Details:
Private placement will be used to advance two Phase 2 clinical trials of MS1819 in patients with cystic fibrosis.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
